715 related articles for article (PubMed ID: 29699580)
1. Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.
Dufresne SS; Boulanger-Piette A; Bossé S; Argaw A; Hamoudi D; Marcadet L; Gamu D; Fajardo VA; Yagita H; Penninger JM; Russell Tupling A; Frenette J
Acta Neuropathol Commun; 2018 Apr; 6(1):31. PubMed ID: 29699580
[TBL] [Abstract][Full Text] [Related]
2. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice.
Hamoudi D; Marcadet L; Piette Boulanger A; Yagita H; Bouredji Z; Argaw A; Frenette J
Hum Mol Genet; 2019 Sep; 28(18):3101-3112. PubMed ID: 31179501
[TBL] [Abstract][Full Text] [Related]
3. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
[TBL] [Abstract][Full Text] [Related]
4. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin protects against muscular dystrophy.
Dufresne SS; Dumont NA; Bouchard P; Lavergne É; Penninger JM; Frenette J
Am J Pathol; 2015 Apr; 185(4):920-6. PubMed ID: 25708645
[TBL] [Abstract][Full Text] [Related]
6. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice.
Hamoudi D; Bouredji Z; Marcadet L; Yagita H; Landry LB; Argaw A; Frenette J
Hum Mol Genet; 2020 Feb; 29(3):483-494. PubMed ID: 31943048
[TBL] [Abstract][Full Text] [Related]
7. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
8. Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction.
Dufresne SS; Boulanger-Piette A; Bossé S; Frenette J
Receptors Clin Investig; 2016 May; 3(2):e13231-e13236. PubMed ID: 27547781
[TBL] [Abstract][Full Text] [Related]
9. Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair.
Bouredji Z; Hamoudi D; Marcadet L; Argaw A; Frenette J
Mol Ther Methods Clin Dev; 2021 Jun; 21():559-573. PubMed ID: 33997104
[TBL] [Abstract][Full Text] [Related]
10. Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity.
Trajanovska S; Ban J; Huang J; Gregorevic P; Morsch M; Allen DG; Phillips WD
J Physiol; 2019 Sep; 597(18):4831-4850. PubMed ID: 31340406
[TBL] [Abstract][Full Text] [Related]
11. Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids.
Atilano-Miguel S; Barbosa-Cortés L; Ortiz-Muñiz R
Bol Med Hosp Infant Mex; 2022; 79(5):275-283. PubMed ID: 36264895
[TBL] [Abstract][Full Text] [Related]
12. RANKL Inhibition Reduces Cardiac Hypertrophy in
Marcadet L; Juracic ES; Khan N; Bouredji Z; Yagita H; Ward LM; Tupling AR; Argaw A; Frenette J
Cells; 2023 Jun; 12(11):. PubMed ID: 37296659
[TBL] [Abstract][Full Text] [Related]
13. Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.
Jayash SN; Hamoudi D; Stephen LA; Argaw A; Huesa C; Joseph S; Wong SC; Frenette J; Farquharson C
Calcif Tissue Int; 2023 Oct; 113(4):449-468. PubMed ID: 37470794
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin and β
Dufresne SS; Boulanger-Piette A; Frenette J
Am J Pathol; 2017 Mar; 187(3):498-504. PubMed ID: 28041995
[TBL] [Abstract][Full Text] [Related]
15. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
16. Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice.
Boulanger Piette A; Hamoudi D; Marcadet L; Kyomi Labelle F; Ovidiu David R; Bossé S; Argaw A; Frenette J
PLoS One; 2018; 13(6):e0198408. PubMed ID: 29879154
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.
Boulanger Piette A; Hamoudi D; Marcadet L; Morin F; Argaw A; Ward L; Frenette J
Curr Osteoporos Rep; 2018 Oct; 16(5):541-553. PubMed ID: 30225627
[TBL] [Abstract][Full Text] [Related]
18. Muscle RANK is a key regulator of Ca2+ storage, SERCA activity, and function of fast-twitch skeletal muscles.
Dufresne SS; Dumont NA; Boulanger-Piette A; Fajardo VA; Gamu D; Kake-Guena SA; David RO; Bouchard P; Lavergne É; Penninger JM; Pape PC; Tupling AR; Frenette J
Am J Physiol Cell Physiol; 2016 Apr; 310(8):C663-72. PubMed ID: 26825123
[TBL] [Abstract][Full Text] [Related]
19. An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice.
Widrick JJ; Jiang S; Choi SJ; Knuth ST; Morcos PA
Muscle Nerve; 2011 Oct; 44(4):563-70. PubMed ID: 21922468
[TBL] [Abstract][Full Text] [Related]
20. Hypochlorous acid exposure impairs skeletal muscle function and Ca
Lea TA; Panizza PM; Arthur PG; Bakker AJ; Pinniger GJ
J Physiol; 2023 Dec; 601(23):5257-5275. PubMed ID: 37864413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
